Amgen Files Lawsuit Against Roche for Patent Infringement

11-Nov-2005

Amgen announced that it filed a lawsuit in the United States District Court in Boston, Massachusetts against F. Hoffmann-LaRoche Ltd., Roche Diagnostics GmbH, and Hoffmann-LaRoche, Inc., seeking a declaration by the Court that defendants' importation, use, sale or offer to sell a pegylated version of recombinant human erythropoietin infringe Amgen's patents. Amgen alleges infringement of six U.S. patents owned by Amgen that claim erythropoietin (EPO) products and pharmaceutical compositions, and processes for making EPO. Amgen seeks a permanent injunction preventing the defendants from making, importing, using, offering for sale or selling recombinant human EPO, including pegylated EPO, in the United States.

Amgen markets a recombinant human EPO product in the United States as EPOGEN(R) (Epoetin alfa) for the treatment of anemia associated with chronic renal failure for patients on dialysis. Amgen's patent rights on erythropoietin protect Amgen's breakthrough inventions.

Other news from the department politics & laws

Most read news

More news from our other portals

So close that even
molecules turn red...